Game Changer in ADHD Care: Glenmark’s Generic Adderall Hits Shelves This May

Glenmark Pharmaceuticals Inc., USA, has made a statement regarding the forthcoming launch of its generic equivalent of Adderall® tablets in May 2025. The generic drug has the same active ingredients as the brand drug—Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate—and will be available in various strengths: 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg. The product has been cleared by the FDA as therapeutically equivalent and bioequivalent to Teva Women's Health's Adderall® tablets.

 

Adderall® is a highly prescribed drug in the United States for the treatment of attention-deficit hyperactivity disorder (ADHD) and narcolepsy. The market for Adderall® tablets is large, with sales totaling around $421.7 million during the 12 months through February 2025. Glenmark's launch is intended to meet persistent supply shortages that have impacted patients dependent on this essential medication.

 

The generic version of Adderall tablets will be available by prescription via normal pharmaceutical distribution channels beginning May 2025, offering a more convenient and potentially less expensive alternative for patients and healthcare professionals. This action should greatly reduce the existing shortage problems and enhance treatment continuity for individuals with ADHD and narcolepsy.

Source: BusinessUpturn.com